Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: Semaglutide for Albuminuria in Obesity
NCT04889183Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2022
- Primary completion
- May 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in obesity and albuminuria comparing Semaglutide with Placebo (2 arms). Primary endpoint: Urinary Albumin:Creatinine Ratio at 24 weeks. Started Mar 2022; status: completed.
02
Drugs
03
Conditions
obesityalbuminuria
Beyond the preview
Go deeper on NCT04889183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889183.